GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Invitae Corp (OTCPK:NVTAQ) » Definitions » Capex-to-Operating-Cash-Flow

Invitae (Invitae) Capex-to-Operating-Cash-Flow : 0.00 (As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Invitae Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Invitae's Capital Expenditure for the three months ended in Sep. 2023 was $-1.93 Mil. Its Cash Flow from Operations for the three months ended in Sep. 2023 was $-66.90 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Invitae Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Invitae's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invitae Capex-to-Operating-Cash-Flow Chart

Invitae Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Invitae Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Invitae's Capex-to-Operating-Cash-Flow

For the Diagnostics & Research subindustry, Invitae's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invitae's Capex-to-Operating-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Invitae's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Invitae's Capex-to-Operating-Cash-Flow falls into.



Invitae Capex-to-Operating-Cash-Flow Calculation

Invitae's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-53.309) / -492.961
=N/A

Invitae's Capex-to-Operating-Cash-Flow for the quarter that ended in Sep. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-1.928) / -66.895
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Invitae  (OTCPK:NVTAQ) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Invitae Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Invitae's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Invitae (Invitae) Business Description

Traded in Other Exchanges
Address
1400 16th Street, San Francisco, CA, USA, 94103
Invitae Corp operates as a genetic information company in diagnostic and research industry. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders and other hereditary conditions.
Executives
Ana J. Schrank officer: Chief Financial Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
Robert M. Guigley officer: Chief Commercial Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
Robert Iv Dickey officer: See Remarks 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Jeff Parsons officer: See remarks 2575 AUGUSTINE DRIVE, SANTA CLARA CA 95054
Robert L Nussbaum officer: Chief Medical Officer 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Thomas Brida officer: General Counsel 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Robert F. Werner officer: Chief Accounting Officer 2500 FABER PLACE, PALO ALTO CA 94303
Yafei Wen officer: Chief Financial Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
Kenneth D. Knight officer: Chief Operating Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
William H Osborne director 1415 WEST 22ND STREET, SUITE 1100, OAK BROOK IL 60523
Sean E George director, officer: CEO 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Shelly D Guyer officer: Chief Financial Officer 1025 GREEN STREET, SAN FRANCISCO CA 94133
Katherine Stueland officer: Chief Commercial Officer 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Geoffrey Crouse director 3130 GATEWAY DRIVE, P O BOX 5625, NORCROSS GA 30091-5625
Jason W. Myers director, other: President, Oncology C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301

Invitae (Invitae) Headlines

From GuruFocus

Q2 2023 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q2 2022 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q2 2021 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q4 2020 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q1 2020 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Invitae Corp M&A Call Transcript

By GuruFocus Research 02-14-2024

Q4 2021 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024